My laboratory is interested on biomolecular and biopharmaceutical engineering aiming the investigation, analysis, and integration of genomic and proteomic data towards the design of therapeutic proteins. This will lead us to guide protein engineering through molecular medicine and bio-nanotechnology in a mid- to long-term timeframe. At the center of our biopharmaceutical development we aim at rational antibody engineering as our approach to validate our theoretical concepts. We consider the use of intracellular and extracellular small-domain antibodies to be exemplary in our rational protein engineering strategies. We have applied our stability engineering strategies to the construction of hyper-stable and effective small antibodies. We want to be able to use our hyperstable frameworks for the construction of small domain antibodies in a number of examples, ranging from HIV to cancer and in model domains to a designed catalytic intrabody. My interest in protein therapeutics may stem the discovery and development of new leads for biopharmaceuticals in the area of infectious diseases, cancer and neurological problems. The focus on the discovery and development of a new class of therapeutic antibodies and efficient display technologies may allow the rapid identification of binding proteins with high affinity and specificity. The domain antibodies combine the advantages of conventional antibodies with the benefits of small-molecule drugs. In addition , we plan to adapt our antibody domain platform to other areas as inhibition of extracellular enzymes and cell surface receptors. Development of better characterization assays and monitoring of antibody therapy in patients, including immunogenicity and pharmacokinetics to biosimilars is current to our work. The evaluation of quality, efficacy and safety attributes of biosimilar antibodies and fusion proteins is at the centre of our clinical collaborations.